AUTHOR GUIDELINES

I. Submission

Spontaneous contributions are welcome and should be sent to Executive Editor Jakob McKernan at *mckernan@lexxion.eu*.

II. Quality statement, editorial review and general terms of publication

Only submissions of excellent quality will be accepted in EPLR. Responsibility of the factual accuracy of a paper rests entirely with the author. All publications must clearly distinguish themselves from the status quo of discussions – in particular through sufficiently broad footnoting and referencing – and provide an added value to those discussions. Contributions should not have been published, nor be pending publication elsewhere. Publications not up to this quality standard will be rejected.

Submission of a manuscript does not imply claim for publication. **Articles** will undergo a process of double blind peer-review for accuracy, quality and relevance, while **reports and case notes** will be peer-reviewed by the Reports Editor. Optionally, before submitting a manuscript, the editors may be contacted regarding the suitability of a given topic for EPLR.

The manuscript must also be complete and final in terms of formulation and factual information so that no major corrections – only of type-setting errors or the like – will be necessary after type-setting, when an edited version will be returned to the author. Subsequent requests for corrections cannot be processed.

III. Type, format and style of contributions

All contributions must comply with the minimum formatting requirements laid out hereunder. Contributions not respecting these formatting requirements will be returned to the author. All contributions use footnotes, but not a list of references.

The EPLR publishes three types of contributions: articles, reports and case notes. Upon submission, authors are requested to indicate the type of contribution they are submitting.

Format and Length

Articles are contributions of an academic nature, discussing a pharmaceutical law topic in the context of existing literature and jurisprudence. The purpose of an article is to contribute to a larger debate in pharmaceutical law or policy and to deeply engage with and critically reflect upon the core questions of pharmaceutical regulation. An article should be between 4,000–8,000 words (including footnotes) in length (MS Word Format, in British English). Longer articles are accepted on a case-by-case basis if more space is required by the topic. Each article is preceded by a short abstract (without heading) of five to six sentences.

Reports can either reflect on current legislative or judicial developments in a specific EU country or provide an overview of a topic of recent development in pharmaceutical law and policy on the EU level. In contrast to articles, reports are more factual and aim at providing the

reader an introduction to or overview of a specific regulatory development or approach. They highlight a topic of particular interest relating to legal developments at EU level, in the EU Member States or third countries with a clear link to European pharmaceutical law. The reports provide readers with the facts, as well as some critical and personal comments. A report should be between 2,000-3,500 words (including footnotes) in length.

Case Notes discuss relevant jurisprudence in the area of pharmaceutical law. The focus is on judgements provided by the Court of Justice of the European Union, but relevant international or national jurisprudence can also be submitted in agreement with the editors. A case note should be between 2,000–3,000 words (including footnotes) in length. Their overall structure shall be divided in the Facts, the Judgment and the Comment. The case note shall be headed by a short headline in bold that summarises the main issue of the case and the reference of the case in Italics, including its publication in the official journal of the respective Court. In cases where the judgment is not (yet) final, this fact shall be indicated.

Presentation

Title

Every word in the title should be capitalised except for conjunctions (Headline Capitalisation). The title's length should not exceed three lines after typeset (max. 150 characters including spaces).

Subtitles are allowed and should also not exceed the 3 lines rule (max. 200 characters including spaces).

Authors' details

Author(s) details should be included in a first asterisk footnote (*) inserted after the author's/authors name(s).

Example:

Article Title

Christopher Bovis[*]

.....

[*] Prof. Christopher Bovis, H.K. Bevan Chair in Law, Law School, University of Hull; Managing Editor of the European Procurement and Public Private Partnership Law Review (EPPPL). For correspondence: <bovis@xyz.com>.

To do so: In the References ribbon tab, click the Footnotes launcher (lower right corner in the Footnotes section). There, place an asterisk into the Custom mark: box, then click Insert, and type your footnote text.

All further footnotes should be numbered sequentially in superscript in the text ***outside* punctuation marks**.

Tables and figures

Tables and figures should be submitted on extra pages. Every table should have a title. The relevant sources of the data presented or of the tables or figures themselves should be indicated. Within the text, the position at which a table is to be included should be marked by '[TABLE …]', the tables and figures being clearly numbered. Every table should be referred to.

To ease the typesetting process, please keep formatting within tables to a minimum (eg avoid merged cells or the use of vertical text for headings).

Abstract

Each article is preceded by a **short abstract** (without heading) in italics of five to six sentences, without footnotes (approx. 200 words)

Headings

Every word in a heading should be **capitalised** except for conjunctions (Headline Capitalisation). The headings should be structured as follows:

H1: I. (starting with the introduction)

H2: 1.

H3: a.

H4: aa.

IV. Quotation and referencing

All references should be included in the footnotes: **no final bibliographies are allowed**. The reference style is **OSCOLA**. All contributions should be submitted in **British English**.

Full guide:

http://www.law.ox.ac.uk/published/OSCOLA_4th_edn.pdf

Quick guide:

https://www.law.ox.ac.uk/sites/files/oxlaw/oscola_4th_edn_hart_2012quickreferenceguide.pdf